Listen to Mahatme et al summary which evaluated and compared the efficacy of the combination therapy of Montelukast with two different antihistamines in allergic rhinitis patients.
Listen to Walekar et al JOURNAL TALK which assessed the bioequivalence of fexofenadine 120 mg+montelukast 10 mg fixed dose combination with separate formulations of fexofenadine and montelukast administered concurrently at the same dose levels.
Listen to a Journal talk on Nayak et al comparing efficacy and safety of Fexofenadine+Montelukast vs Levocetirizine +Montelukast.
Articles
No benefit was observed using Bilastine plus Montelukast in providing relief from SARC symptoms as per SKY study. 42% better patient satisfaction was observed when Montelukast is combined with Fexofenadine. (Cingi et. al)
SKY study questions the additive effects of the Bilastine and Montelukast combination. There is no benefit of using Bilastine plus Montelukast to provide relief from SARC symptoms. Allegra-M is the only Fexofenadine and Montelukast combination published for bioequivalence in the Indian Journal of Pharmaceutical Sciences.
Emerging evidence from evolving body of covid-19 research depicts that Fexofenadine and Montelukast are the only anti-histamine & LTRA found promising for covid 19 virus Mpro substrate binding, mediating SARS-CoV-2 virus replication and transcription. For managing patients with Allergic Rhinitis, Allegra M is a trusted combination of Fexofenadine and Montelukast.
Montelukast and Fexofenadine showed better improvement in the symptoms of allergic rhinitis and a better global impression as compared to Montelukast and Levocetirizine. In the era of evidence-based medicine, Allegra M (Montelukast + Fexofenadine) is a trusted choice for allergic rhinitis patients.
Fexofenadine & Montelukast are the ONLY anti-histamine & LTRA found promising for COVID-19 virus Mpro substrate binding (Over 2000 evaluated candidates)
This is a compact overview of recommendations by the EUFOREA expert teams on allergic airway diseases and allergen-specific immunotherapy (AIT) is based on investigation of the current COVID-19 literature.
Infographic
Allegra-M offers 2X faster disintegration as compared to other fexo-monte brands, providing assured patient relief from symptoms of allergic rhinitis.
Allegra-M is steps ahead in safety and efficacy in Indian patients vs levocetirizine-montelukast combinations. Onset of action, TNSS reduction, additional anti-inflammatory coverage? Allegra-M scores on all these parameters over levocetirizine-montelukast combinations.
Bi-layered and single-layered formulations- Same or different?
Allegra-M, an innovative bi-layered formulation provides 2x superior outcomes vs single-layered brands.
Are all fexofenadine-montelukast brands the same? Allegra-M is an innovative bi-layered formulation of fexofenadine and montelukast which ensures BETTER DISSOLUTION PROFILE than monolayered marketed products.
JMulti-dimensional efficacy gives Allegra-M supremacy over others in AR management.
Join us for Allergy and Immunotherapy module (Endorsed by ICS)
Fexofenadine+montelukast or monteleukast+levocetrizine? Allegra-M is more effective than levocetirizine+ montelukast across all key dimensions in the treatment of Allergic rhinitis. Click here to read more.
Which AH+ montelukast combination would you choose for your AR patients? One with no influence on the ability to drive or one which can influence the patient’s ability to drive?
Would you trust a FDC with zero evidence or a FDC with years of trust and credibility?
Built on decades of trust and clinical evidence, Allegra-M is a superior choice over Bilastine and Montelukast combination.
Allegra-M offers innovative bi-layered technology for superior treatment outcomes. Bi-layered technology allows uninterrupted release of both APIs in presence of each other.
Preparing for an upcoming wave of respiratory allergies? Choose the right Fexofenadine and Montelukast combination. Allegra-M is proven to offer 2X faster disintegration for superior treatment outcomes over other Fexo and Monte brands.
Allegra-M is 3 steps ahead of the levocetirizine and montelukast combination in terms of efficacy, safety, and patient compliance. Allegra-M is your trusted choice for managing allergic rhinitis.
Indian patients have shown to respond better to Allegra-M over levocetirizine and montelukast.
Allegra-M scores over levocetirizine and montelukast across all the key dimensions of efficacy such as disease severity, degree of relief, onset of action, and inflammatory mediator coverage.
Allegra-M is the only bioequivalent Fexofenadine and Montelukast combination published in the Indian Journal of Pharmaceutical Sciences. Allegra-M (Fexofenadine and Montelukast) is the superior synergistic combination.
Indian clinical studies have shown that better patients respond better to Fexofenadine plus Montelukast (Allegra-M) vs Levocetirizine plus Montelukast in the management of Allergic Rhinitis.
Backed with solid clinical evidence, Allegra-M is a superior combination over Levocetirizine+Montelukast & Bilastine+Montelukast.
Allegra M is the only Fexofenadine & Montelukast combination published in IJPS for its Bio-equivalence. It is an innovative and quality-driven formulation with a unique manufacturing process that ensures a better dissolution profile.
Allegra M is the ONLY Fexofenadine & Montelukast combination published in IJPS for its Bio-equivalence. It is an innovative and quality-driven formulation.
When developing a fixed dose combination, pharmacokinetics of the individual drugs should remain unchanged to ensure optimum patient outcomes. Allegra-M is bioequivalent to innovator individual tablets of same strengths administered concurrently.
Fexofenadine and Montelukast show superior efficacy, safety, and compliance as compared to Levocetirizine and Montelukast. Allegra-M is the preferred choice for your allergic rhinitis patients.
Indian patients respond better to Fexofenadine and Montelukast combination as compared to Levocetirizine and Montelukast. Allegra-M is the preferred choice for Allergic Rhinitis patients.
Built on your trust and decades of credibility, Allegra-M is the only Fexofenadine and Montelukast combination published for bioequivalence in the Indian Journal of Pharmaceutical Sciences.
Allegra M is a superior synergistic combination offering better patient outcomes as compared to Bilastine Montelukast combination. SKY study questions the additive effect of the Bilastine Montelukast combination.
Allegra-M is proven to offer 2X faster disintegration for superior treatment outcomes OVER other Fexofenadine and Montelukast brands. Allegra-M, Your trusted choice for managing allergies amidst the pandemic.
Allegra-M is formulated with an innovative bi-layered technology for superior treatment outcomes. Bi-layered technology allows uninterrupted release of both APIs in presence of each other.
Allegra-M is proven to offer 2X faster disintegration for superior treatment outcomes over other fexofenadine and montelukast brands.
Allegra-M is proven to offer 2X faster disintegration for superior treatment outcomes over other fexofenadine and montelukast brands. Allegra M- Your trusted choice for managing allergies amidst the pandemic.
Fexofenadine & Montelukast is the only anti-histamine and LTRA combination found promising for COVID 19 virus Mpro substrate binding, inhibiting SARS-CoV-2 main protease, potentially preventing the virus replication. For managing patients with Allergic Rhinitis, Allegra M is a trusted combination of Fexofenadine and Montelukast.
Almost 80% of asthmatic patients have rhinitis, and roughly 30% of rhinitis patients have asthma. Treating allergic rhinitis in asthma reduces hospitalizations by 61%. Allegra-M is the only Fexofenadine and Montelukast combination published for bioequivalence in the Indian Journal of Pharmaceutical Sciences.
Allegra M (Fexofenadine and Montelukast) is a preferred combination over the other antihistamine & leukotriene antagonist combinations. Allegra-M is clinically proven to offer superior efficacy, superior safety and better patient compliance over other combinations.
Allegra M (Fexofenadine and Montelukast) is a superior synergistic combination over the Bilastine and Montelukast combination. Bilastine is not approved by the USFDA, and the Bilastine & Montelukast combination lacks published evidence for managing allergic rhinitis.
The combination therapy of Montelukast with Fexofenadine provides synergistic effects, thereby reducing the symptoms effectively. Evaluation of TNSS revealed significant differences Vs Levocetirizine & Montelukast combination when compared from baseline to 4th week in both groups. The decrease in TNSS was more in the Montelukast-Fexofenadine group.
Allegra-M is the trusted choice for managing allergies amidst the pandemic. It is clinically proven formulation to- Reduce the hyperinflammatory cytokine profile.
Downstream pro-inflammatory mediators.
Fexofenadine along with montelukast (Allegra M) is a superior synergistic combination than other antihistamine combinations as it scores over them across multiple parameters in the management of allergic rhinitis.
Fexofenadine along with montelukast (Allegra M) is a more effective synergistic combination than other antihistamine combinations in the management of allergic rhinitis. SKY study proved that there is no benefit of using Bilastine plus Montelukast to provide relief from SARC symptoms beyond those provided by either agent alone.
Allegra®-M (Fexofenadine & Montelukast) is a superior synergistic combination offering better patient outcomes compared to Bilastine & Montelukast combination.
Fexofenadine use is not associated with an increased risk of major birth defects, spontaneous abortion and risk of the secondary outcomes such as Preterm birth.
About Allegra®M
Allegra®-M Tablet is a combination of Montelukast and Fexofenadine used in the treatment of allergy symptoms such as runny nose, stuffy nose, sneezing, watery eyes and congestion or stuffiness. It works by blocking the action of another chemical messenger (histamine) responsible for runny nose, watery eyes and sneezing.
